Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Preferred Stock Liabilities (2021)

Historic Preferred Stock Liabilities for ARS Pharmaceuticals (SPRY) over the last 1 years, with Q4 2021 value amounting to $54.8 million.

  • ARS Pharmaceuticals' Preferred Stock Liabilities changed N/A to $54.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $54.8 million, marking a year-over-year change of. This contributed to the annual value of $54.8 million for FY2021, which is N/A changed from last year.
  • As of Q4 2021, ARS Pharmaceuticals' Preferred Stock Liabilities stood at $54.8 million.
  • Over the past 5 years, ARS Pharmaceuticals' Preferred Stock Liabilities peaked at $54.8 million during Q4 2021, and registered a low of $54.8 million during Q4 2021.